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Granular cell tumor (GCT) is a Schwann cell related benign neoplasm of soft tissue. GCT is an uncommon entity that occurs in a
wide variety of body sites, but it is generally presented in the skin, oral cavity, superficial soft tissue, and respiratory and digestive
tracts. Most of the GCTs are benign but clinically and radiologically these may mimic malignancy. Histopathological diagnosis
is gold standard for establishing the true nature of the lesion. GCT is most commonly solitary but in about 10% of cases can be
multifocal, usually involving various skin and soft tissue sites versus involving various internal sites.Therefore, these can involve skin
and soft tissue or submucosa and viscera. GCT is usually benign; however, local recurrence is common due to incomplete removal.
Malignant cases are rarely reported in 1-2% of cases. In this study, we report clinical and histopathological findings of a 36-year-old
woman with metachronous GCT in breast and scalp. The clinical features raise the question of whether these are metachronous
benign GCTs or whether this is establishment of malignant behavior. The aim of this report is to present the histopathological and
clinical features of GCT and the diagnostic challenge of differentiating benign from malignant GCT.
1. Introduction
Granular cell tumor, first described in 1926, was thought to
be derived from skeletal muscle cells and termed “granular
cell myoblastoma” by Abrikossoff [1]. Nowadays, the most
accepted theory is Schwann cell origin, because of the S100
protein expression in tumor cells and the similarities between
the ultrastructural features of the tumor cells and Schwann
cells [2].
GCT is an uncommon tumor that occurs in a wide variety
of body sites but is mainly found in the skin, oral cavity,
superficial soft tissue, and respiratory and digestive tracts
[3]. GCT of the breast is really rare. It accounts for 8.5% of
all GCTs [4]. GCT arises from interlobular breast stroma or
cutaneous tissue of breast [1, 2, 5]. GCT is usually benign.
Malignant cases are rarely reported, with an incidence of
1-2% [6]. Recognition of benign GCT is important, since
these are infrequently diagnosed preoperatively; thesemay be
confused clinically and radiologically with malignant lesions.
Herein we report the clinical and histopathological find-
ings in a case of a 36-year-old woman with a clinical
presentation of metachronous GCTs, a palpable, painless
mass in the breast skin, and then another mass eighteen
months later in the scalp. A literature review is performed and
discussion between benign and malignant GCT is presented.
2. Case Report
Case 1. A 36-year-old woman presented with a firm, fixed,
painless palpable skin mass, approximately measured 2 cm
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diameter, in the lower-inner quadrant of the left breast
skin (Figure 1(a)). She had pruritus but had neither nipple
discharge, nor peau d’orange appearance. A slowly growing
mass was realized a few years ago. The patient had no
previous surgical intervention of the breast. Macroscopically
an ill-defined, firm, grey-white lesion measured approxi-
mately 1.6 × 0.9 × 0.9 cm in the subepidermal breast tissue.
Histopathologically, this lesion was located in the dermis
and subcutaneous fat tissue without epidermal infiltration.
Minimal acanthosis without reactive pseudoepitheliomatous
hyperplasia was detected (Figure 1(b)). The tumoral lesion
was ill-defined and had an infiltrative growth pattern but
the ductal-lobular unit of the breast was not involved
(Figure 1(c)). The lesion was composed of compact nests
and sheets of large polygonal tumoral cells, containing
large eosinophilic granular cytoplasm and relatively small
round or oval nuclei (Figure 1(d)). Focally, small nerves were
surrounded by granular cells. Tumor cells were expressing
S100 protein strongly and diffusely (Figure 1(e)) and CD68
in cytoplasmic inclusions surrounded by halos (Figure 1(f))
and were completely negative for p53 (Figure 1(g)), pan-
cytokeratin (cytokeratin AE1/AE3), estrogen receptor, and
progesterone receptor. Ki-67 labeling index of tumor was
approximately 1% (Figure 1(h)).
Case 2. Eighteen months later, the patient presented with a
mass on the vertex of scalp (Figure 2(a)). This lesion was 1.7
× 1.3 × 0.8 cm in size and with scale-crusted appearance.This
tumoral lesion was located in dermis and was well defined
macroscopically and microscopically, in contrast to breast
lesion. We observed prominent reactive pseudoepithelioma-
tous hyperplasia in the scalp lesion (Figure 2(b)). This lesion
had similar histological, cytomorphological, and immuno-
histochemical features to the previous lesion (Figures 2(c)
and 2(d)); Ki-67 was relatively overexpressed in the scalp
lesion (6% of the nuclei of neoplastic cells) (Figure 2(e)).
Tumors cell expressed weak and mild p53 (Figure 2(f)).
Similar to previous lesion tumor cells were diffusely positive
for S100 (Figure 2(g)) and negative for pancytokeratin (cytok-
eratin AE1/AE3) (Figure 2(h)).
In both of the lesions none of the histological criteria
of malignant behavior was detected such as (1) spindling
of the tumor cells, (2) presence of vesicular nuclei with
large nucleoli, (3) increased mitotic rate, (4) high nuclear to
cytoplasmic ratio, (5) pleomorphism, or (6) necrosis.
3. Discussion
GCTwas first described in 1926 by Abrikossoff on tongue and
postulated amyogenic origin as “granular cell myoblastoma.”
Initially GCTs were considered to arise from myocytes,
histiocytes, fibroblast, or intestinal mesenchymal cells. The
most widely accepted theory has been that of Schwann
cell origin, because of positivity of the tumor cells for the
S100 protein and the similarities between the ultrastructural
features of the tumor cells and those of Schwann cells.
GCT occurs in patients of all ages, commonly observed
between the fourth and sixth decades of life. It is more
common in women than men and very rare in childhood [7–
9].
GCT arises throughout the body and the most common
presentation is a solitary painless nodule, located in the
skin, tongue, and oral cavity and less frequently in breast,
gastrointestinal and respiratory tracts, female genital system,
smooth muscle, or striated muscle [9]. According to the
literature, 30% to 45% of GCTs are observed in the skin of
the head and neck. When compared to other studies, Dupuis
and Coard found a notable difference in the distribution of
GCT. In their study, lesions of the tongue accounted for fewer
than expected, while lesions of the breast and vulva were
considerably increased [8].
GCT of the breast is rare, with a percentage of 8.5 among
all GCTs [10, 11]. Breast GCT more commonly occurs in
premenopausal women and, according to reports, especially
in African-American women [2, 12]. GCT is found most
frequently in the upper inner quadrant of the breast, differ-
entiating it from carcinomas which is frequently in the outer
quadrants. In our case, the GCT tumor was located in the
lower inner quadrant of the left breast as a dermal infiltration.
GCTs are usually benign solitary Schwannian neu-
ral tumors. Local recurrence may occur with incomplete
removal. Malignant behavior of GCT is rare (<2%). Although
most of GCTs are solitary lesions, in about 15 to 25% of
the cases GCT can be multifocal, simultaneously involving
the skin and soft tissue or simultaneously involving the
submucosa and viscera. Multiplicity should not be taken as
evidence for malignancy [13]. Familial occurrence has been
reported, but there is no clear evidence for a syndrome [14].
Malignant GCTs usually occur in older population and
tend to be larger than their benign counterparts. Malignant
GCTs grow rapidly, often ulcerate, invade locally, and tend
to spread with extensive metastases. Generally, it is well
accepted that benign GCTs do not transform into malignant
ones; malignant GCTs arise de novo. In contrast, Chen et al.
presumed that malign GCT may result from the malignant
transformation of benign GCT [15]. Malignant GCTs often
recur locally with multiple skin satellite nodules. Metastases
most commonly develop in the lymph nodes, lungs, bones,
rarely the intestines, liver, or brain. According to Fanburg-
Smith et al., tumor-related deaths occurred in 11 of 28
patients, with a median time of 3 years (range, 1 yr–9 yr) [16].
Grossly, benign GCT typically forms an oval nodule,
smaller than 3 cm, that varies from being well or poorly
circumscribed with a pale and yellow tan on cut surface.
Occasionally, tumors reach the size of 5 cm or more. Dupuis
and Coard reported the range of diameter as 0.2 cm to 10 cm
in 130 benign GCT cases of various sites [8]. Malignant
GCTs have similar gross appearance but tend to be larger
than benign lesions; however, malignant GCT can also be
small. Microscopically most of malignant GCTs are poorly
circumscribed. About two-thirds of the GCTs are located in
cutaneous, subcutaneous, or submucosal tissues and some of
these cases are associatedwith pseudoepitheliomatous hyper-
plasia of the overlying epidermis or mucosal epithelium. It is
reported that GCT of breast may arise in either interlobular
breast stroma or the skin overlying breast [1, 2, 11].The cells of
GCT which are round, polygonal, or slightly spindle shaped
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Figure 1: (a) Subcutaneous mass of breast. (b) Minimal acanthosis and epidermal pseudoepitheliomatous hyperplasia (H&E, ×50). (c) Ill-
defined tumoral lesion with infiltrative pattern (H&E, ×100). (d) Compact nests and sheets of polygonal tumor cells (H&E, ×200). (e) Tumor
cells expressing S100 (×100). (f) Tumor cells expressing CD68 (×200). (g) Tumor cells weakly expressing p53 (×200). (h) Ki-67 proliferation
expressing approximately 1%.
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Figure 2: (a) Subcutaneous mass on the vertex of the scalp with ulcerated surface. (b) Reactive pseudoepitheliomatous hyperplasia of
epidermis (H&E, ×100). (c) Polygonal tumor cells forming nests (×200). (d) Tumor cells with large eosinophilic granular cytoplasm and oval
nucleus with nucleoli (H&E, ×400). (e) Tumor cells showing approximately 6% Ki-67 proliferation index (×200). (f) Tumor cells expressing
p53weakly andmildly (×200). (g) Tumor cells expressing S100 protein diffusely and strongly. (h) Tumor cells immunohistochemically negative
for cytokeratin AE1/AE3 (×200).
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and are characterized by large and granular cytoplasm. They
have small and hyperchromatic or large and vesicular nuclei.
Granular cells and peripheral nerves have close association.
InGCT, there are small nerves that are invaded or surrounded
by the granular cell clusters.
Immunohistochemically, GCT is consistently positive for
S100 protein, NSE, various myelin proteins, and negative
for muscle cell and epithelial markers. GCTs are strongly
positive for macrophage antigen CD68, specifically in the
cytoplasmic lysosomal granules with clear halo around these,
and this lysosomal granule excludes other tumors that may
have granular features. GCTs are also alpha-inhibin positive
[17–19].
In 1998, Fanburg-Smith et al. established that six histo-
logical criteria could predict malignant behavior [16], such as
sarcomatoid spindling of the tumor cells, presence of vesicu-
lar nuclei with large nucleoli, increasedmitotic rate (2mitoses
per 10 high-power fields), high nuclear to cytoplasmic ratio,
pleomorphism, and necrosis. If a GCT demonstrates three or
more of these criteria, it is classified as “malignant” and those
that show one or two criteria are classified as “atypical,” and
if it exhibits none of the criteria or only focal pleomorphism,
it is classified as “benign.” Most of the malignant tumors,
however, had at least 5 or 6 of the criteria andmost malignant
cases had necrosis or increased mitotic activity. They also
demonstrated that Ki-67 and p53 were significantly higher in
atypical and malignant tumors than in benign ones [16].
According to histological and cytological features,
Argenyi suggested that malignant GCTs might be classified
into two types [20]. The first type of malignant GCT is more
common and essentially appears identically to a benign
tumor; because cytologic atypia or mitotic activity may not
be reliable biologic indicators in this form, diagnosis of
malignancy should be made by clinicopathologic correlation
(large size, rapid growth, ulceration, necrosis, sarcomatoid
spindling, and lymphatic and vascular invasion). Vesicular
nuclei with large nucleoli and mitotic rate are more than 2
mitoses/10 HPF and are additional findings for malignancy.
The second type of malignant GCT is quite rare. In this
type, either primary GCT or metastases display conventional
malignant histological and cytological features. Malignant
GCT cells express similar immunohistochemical features to
those of a benign tumor, with the exception Ki-67 labeling
index being higher and p53 expression being prominent [20].
According to Nasser et al., some of the criteria proposed
by Fanburg-Smith, such as pleomorphism and increased
nuclear-to-cytoplasmic ratio, are subject to interobserver
variation and show weak reproducibility among different
pathologists, complicating the diagnostic spectrum [21]. It is
thought that simple, practical, and clear diagnostic criteria
are required. In 2011, Nasser et al. classified the GCTs
based on the presence of necrosis (whether single cell or
en masse) and mitoses. They believe that these are two of
the most reliable and more reproducible criteria associated
with malignancy and designated tumors without these 2
features as “benign” GCTs and those cases demonstrating at
least one of the previously mentioned features as GCTs with
“uncertain malignant potential.”They considered metastases
as the only definitive criterion of malignancy, regardless of
the histopathologic features [21]. Their paper did not have
the large number of cases as in the AFIP paper, but their
conclusions were similar, overall.
p53 expression has been described in neoplastic cells of
MGCTs with a variable frequency, ranging from 5% to 100%
[15, 16, 22, 23]. Ki-67 proliferating index ranged from 10%
to 50% [16, 19, 21, 23]. Le et al. reported that there was not
any significant difference between benign and atypical cases’
Ki-67 expression [19]. Nasser et al. reported mean of Ki-67
labeling index 10.5% in atypical GCTs and 2.7% in benign
GCTs and the difference was statistically significant. There
were no significant differences in p53 expression between
three groups; they all showed strong and diffuse nuclear
staining [21].
Essentially any tumor type may show granular cell
change, and thus the differential diagnosis of true granular
cell tumors is quite broad. Similar morphological properties
can be observed in smooth muscle tumors, rhabdomyoma,
hibernoma, fibroxanthoma, and malignant melanoma [24].
GCT is distinguished from other granular cell lesions with
S100 protein positivity. Epithelial tumors are separated from
granular cell features with keratin positivity and S100 protein
negativity. GCTs of the breast must be distinguished from
benign and malign tumors. Histiocytes and granular cells
are similar in appearance, so that histiocytic inflammatory
lesions must be differentiated. Carcinomas of breast with
apocrine or histiocytoid features may resemble GCT. Car-
cinomas are positive for cytokeratin, and DCIS is usually
present in breast carcinomas.Malignant tumors thatmetasta-
size to breast like malignant melanoma, renal cell carcinoma
must be distinguished from GCT. The most challenging
tumors in differential diagnosis of GCT are granular cell
(spindle cell) melanoma, which is lack of cytoplasmic inclu-
sionswith halos and,when spindled, somedegree of cytologic
atypia and prominent nucleoli and lymphoid responsemay be
present. BRAF can also be helpful in this setting.
In our case, the patient was a 36-year-old woman. The
first lesion was in lower inner quadrant of the left breast; the
second lesion occurring 18 months later was on the vertex of
the scalp.
In immunohistochemical examination of p53, both
lesions were similar (approximately 80% weak nuclear pos-
itivity). Ki-67 labeling index was 1% in the breast GCT and
6% in scalp GCT. Ki-67 expression was slightly higher in
scalp GCT than breast GCT. Another important point was
evaluating Ki-67 away from pseudoepitheliomatous hyper-
plasia, because basal layer of these areas may overexpress Ki-
67. Because of this, we evaluated theKi-67 labeling index areas
of tumor away from epidermis with pseudoepitheliomatous
hyperplasia.
After microscopic and immunohistochemical exam-
ination, both tumors were diagnosed as benign and metach-
ronous according to the diagnostic criteria stated above [16,
21].
Tumor cells are located in dermis and extend to the
subcutaneous septa. Due to subcutaneous septal infiltration
and perineural spread, characteristic findings of the GCT,
incomplete removal, and local recurrence are common prob-
lems.Therefore, complete excision ofGCT is important. After
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complete surgical resection of both tumors with safe surgical
margins, patients could be clinically followed.
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